

NCT ID	NCT05308446
Title	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
Phase	Phase 2
Date Added	2022-04-04
Location	Arizona, United States California, United States Colorado, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States New Hampshire, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Puerto Rico
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	cetuximab, encorafenib, Nivolumab, Braftovi, Erbitux, Opdivo
Tags	MSS/ MMRp

NCT ID	NCT06102902
Title	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
Phase	Phase 1
Date Added	2023-10-26
Location	California, United States Colorado, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	BET Bromodomain Inhibitor ZEN-3694, encorafenib
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT03368963
Title	TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Phase	Phase 1, Phase 2
Date Added	2017-12-11
Location	Georgia, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT02465060
Title	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase	Phase 2
Date Added	2015-06-08

Location	Alabama, United States
	Alaska, United States
	Arizona, United States
	Arkansas, United States
	California, United States
	Colorado, United States
	Connecticut, United States
	Delaware, United States
	District of Columbia, United States
	Florida, United States
	Georgia, United States
	Hawaii, United States
	Idaho, United States
	Illinois, United States
	Indiana, United States
	Iowa, United States
	Kansas, United States
	Kentucky, United States
	Louisiana, United States
	Maine, United States
	Maryland, United States
	Massachusetts, United States
	Michigan, United States
	Minnesota, United States
	Mississippi, United States
	Missouri, United States
	Montana, United States
	Nebraska, United States
	Nevada, United States
	New Hampshire, United States
	New Jersey, United States
	New Mexico, United States
	New York, United States
	North Carolina, United States
	North Dakota, United States
	Ohio, United States
	Oklahoma, United States
	Oregon, United States
	Pennsylvania, United States
	Rhode Island, United States
	South Carolina, United States
	South Dakota, United States
	Tennessee, United States
	Texas, United States
	Utah, United States
	Vermont, United States
	Virginia, United States
	Washington, United States
	West Virginia, United States
	Wisconsin, United States
	Wyoming, United States
	Guam
	Puerto Rico
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Adavosertib, afatinib, Afatinib Dimaleate, Binimetinib, Capivasertib, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Larotrectinib Sulfate, Nivolumab, Osimertinib, palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab emtansine, Ulixertinib, Vismodegib
Tags	MSS/ MMRp
NCT ID	NCT02693535

Title	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Phase	Phase 2
Date Added	2016-02-26
Location	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03599765
Title	Systemic Therapy With or Without Local Consolidative Therapy in Treating Patients With Oligometastatic Solid Tumor
Phase	Phase 2
Date Added	2018-07-26
Location	Arizona, United States Arkansas, United States Hawaii, United States Michigan, United States New Jersey, United States Ohio, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT04599140

Title	SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
Phase	Phase 1, Phase 2
Date Added	2020-10-22
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	CXCR1/2 Inhibitor SX-682, Nivolumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT04653480
Title	Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Phase	Phase 2
Date Added	2020-12-04
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy, Surufatinib, Toripalimab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06014502
Title	Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	Arizona, United States California, United States Louisiana, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	IMGS-001
Tags	MSI-H/ MMRd
<hr/>	
NCT ID	NCT04659382
Title	Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Checkpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2020-12-09
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, TheraSphere, XELOX
Tags	MSS/ MMRp